1. Home
  2. GKOS vs TNGX Comparison

GKOS vs TNGX Comparison

Compare GKOS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$146.06

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

HOLD

Current Price

$28.82

Market Cap

5.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
TNGX
Founded
1998
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
5.1B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
GKOS
TNGX
Price
$146.06
$28.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
10
Target Price
$126.92
$21.78
AVG Volume (30 Days)
928.7K
6.4M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.89
EPS
N/A
N/A
Revenue
$507,442,000.00
$62,384,000.00
Revenue This Year
$23.32
N/A
Revenue Next Year
$27.43
N/A
P/E Ratio
N/A
N/A
Revenue Growth
32.33
48.29
52 Week Low
$73.16
$5.34
52 Week High
$148.62
$34.39

Technical Indicators

Market Signals
Indicator
GKOS
TNGX
Relative Strength Index (RSI) 67.05 53.88
Support Level $96.44 $27.65
Resistance Level N/A $34.39
Average True Range (ATR) 5.65 2.05
MACD 1.60 -0.25
Stochastic Oscillator 98.92 26.85

Price Performance

Historical Comparison
GKOS
TNGX

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Share on Social Networks: